AT7519 is a pyrazole-based multi-cyclin dependent kinase inhibitor with IC50 activity against CDK2, CDK5, and CDK9, of 47, 13, and
In a panel of 26 human tumor cell lines, AT7519 showed potent antiproliferative activity at 40-940 nM. 24h treatment of HCT116 cells showed phosphorylation inhibition of CDK1 substrate PP1a (T320) and CDK2 substrates Rb (T821) and NPM (T199). (2)